Find disease awareness content and relevant supporting materials
Phase III THRIVE-AA2 trial of CTP 543 meets endpoints in alopecia areata
Concert Pharmaceuticals announced positive topline results from its second Phase III clinical trial, THRIVE-AA2, evaluating its oral investigational medicine CTP 543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss
FDA approves Olumiant as first and only systemic medicine for adults with severe alopecia areata.
Eli Lilly and Company and Incyte announced that the FDA has approved Olumiant (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.
Eli Lilly + Incyte's baricitinib improved hair regrowth for alopecia areata patients in second phase III study
Eli Lilly and Company and Incyte announced results from a second Phase III trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA) .
CHMP recommends Olumiant for the treatment of adults with severe alopecia areata.-Eli Lilly.
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).